News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Doe & Ingalls of Maryland and BioVectra Partner to Serve Biotech Companies
June 10, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BALTIMORE--(BUSINESS WIRE)--Doe & Ingalls of Maryland, LLC has signed an exclusive agreement to distribute BioVectra Inc.’s bioprocessing reagents, molecular biology reagents and enzymes in the United States.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Phase 3
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
August 13, 2026
·
3 min read
·
Gabrielle Masson
Layoff Tracker
MindMaze trims Relief staff, Aardvark cuts workforce amid Prader-Willi troubles
August 13, 2026
·
83 min read
·
BioSpace Editorial Staff
Rare diseases
Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
August 13, 2026
·
2 min read
·
Tristan Manalac
Bankruptcy
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale
August 13, 2026
·
2 min read
·
Tristan Manalac
